The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
Open accessAbstract
BACKGROUND: Bruton's tyrosine kinase (BTK) is a mediator of the B-cell-receptor signaling pathway implicated in the pathogenesis of B-cell cancers. In a phase 1 study, ibrutinib, a BTK inhibitor, showed antitumor activity in several types of non-Hodgkin's lymphoma, including mantle-cell lymphoma. METHODS: In this phase 2 study, we investigated oral ibrutinib, at a daily dose of 560 mg, in 111 patients with relapsed or refractory mantle-cell lymphoma. Patients were enrolled into two groups: those who had previously received at least 2 cycles of bortezomib therapy and those who had received less than 2 complete cycles of bortezomib or had received no prior bortezomib therapy. The primary end point was the overall response rate. Secondary end points were duration of response, progression-free survival, overall survival, and safety. RESULTS: The median age was 68 years, and 86% of patients had intermediate-risk or high-risk mantle-cell lymphoma according to clinical prognostic factors. Patients had received a median of three prior therapies. The most common treatment-related adverse events were mild or moderate diarrhea, fatigue, and nausea. Grade 3 or higher hematologic events were infrequent and included neutropenia (in 16% of patients), thrombocytopenia (in 11%), and anemia (in 10%). A response rate of 68% (75 patients) was observed, with a complete response rate of 21% and a partial response rate of 47%; prior treatment with bortezomib had no effect on the response rate. With an estimated median follow-up of 15.3 months, the estimated median response duration was 17.5 months (95% confidence interval [CI], 15.8 to not reached), the estimated median progression-free survival was 13.9 months (95% CI, 7.0 to not reached), and the median overall survival was not reached. The estimated rate of overall survival was 58% at 18 months. CONCLUSIONS: Ibrutinib shows durable single-agent efficacy in relapsed or refractory mantle-cell lymphoma. (Funded by Pharmacyclics and others; ClinicalTrials.gov number, NCT01236391.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, it is not selective for BTK, and multiple mechanisms of resistance, including the C481S-BTK mutation, can compromise its efficacy.”
From Bruton tyrosine kinase degradation as a therapeutic strategy for cancer (2019) · cites this paper as [8]
In the citing paper
“often due to the C481S mutation of BTK, which prevents ibrutinib from forming a covalent bond with BTK and significantly reduces its potency, resulting in median progression-free survival of only ;14 months.8”
From Bruton tyrosine kinase degradation as a therapeutic strategy for cancer (2019) · cites this paper as [8]
In the citing paper
“often due to the C481S mutation of BTK, which prevents ibrutinib from forming a covalent bond with BTK and significantly reduces its potency, resulting in median progression-free survival of only ;14 months.8”
From Bruton tyrosine kinase degradation as a therapeutic strategy for cancer (2019) · cites this paper as [8]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer series in statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,236
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues
Swerdlow, S. H. (2017) · Medical Entomology and Zoology · Cited by 12,933
Revised response criteria for malignant lymphoma.
Cheson, B. D., Pfistner, B., Juweid, M., Gascoyne, R., Specht, L., Horning, S., Coiffier, B., Fisher, R. I., Hagenbeek, A., Zucca, E., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.2403 · Cited by 4,537
Self-citationOptimal two-stage designs for phase II clinical trials.
Simon, R. (1989) · Controlled Clinical Trials · doi:10.1016/0197-2456(89)90015-9 · Cited by 3,636
The Non-Hodgkin's Lymphoma Classification Project (1997) · Blood · doi:10.1182/blood.v89.11.3909 · Cited by 2,456
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
Byrd, J. C., Furman, R. R., Coutre, S. E., Flinn, I. W., Burger, J. A., Blum, K. A., Grant, B., Sharman, J. P., Coleman, M., Wierda, W. G., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215637 · Cited by 2,270
Self-citationChronic active B-cell-receptor signalling in diffuse large B-cell lymphoma
Davis, R. E., Ngo, V. N., Lenz, G., Tolar, P., Young, R. M., Romesser, P. B., Kohlhammer, H., Lamy, L., Zhao, H., Yang, Y., et al. (2010) · Nature · doi:10.1038/nature08638 · Cited by 1,651
Advani, R. H., Buggy, J. J., Sharman, J. P., Smith, S. M., Boyd, T. E., Grant, B., Kolibaba, K. S., Furman, R. R., Rodriguez, S., Chang, B. Y., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.7906 · Cited by 1,128
Self-citationHerman, S. E. M., Gordon, A. L., Hertlein, E., Ramanunni, A., Zhang, X., Jaglowski, S., Flynn, J., Jones, J., Blum, K. A., Buggy, J. J., et al. (2011) · Blood · doi:10.1182/blood-2011-01-328484 · Cited by 807
Self-citation
Flagged first, then by citations
Research works printed but not linked: 1
- 10.2307/2281868 · DOI · Paper page
Cited by
Sorted by citations
Items 501–600 of 1,000
B-cell receptor signaling in chronic lymphocytic leukemia and other B-cell malignancies.
Koehrer, S., & Burger, J. A. (2016) · PubMed · Cited by 31
The proto-oncogene Mer tyrosine kinase is a novel therapeutic target in mantle cell lymphoma
Shi, C., Li, X., Wang, X., Ding, N., Ping, L., Shi, Y., Mi, L., Lai, Y., Song, Y., & Zhu, J. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0584-6 · Cited by 31
Ran, F., Liu, Y., Yu, S., Guo, K., Tang, W., Chen, X., & Zhao, G. (2019) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2019.103367 · Cited by 31
Luo, Q.-Y., Zhou, S.-N., Pan, W., Sun, J., Yang, L., Zhang, L., Qiu, M., & Yang, D. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.114318 · Cited by 32
Self-citationB-cell receptor signaling in the pathogenesis of lymphoid malignancies
Bojarczuk, K., Bobrowicz, M., Dwojak, M., Miązek, N., Zapała, P., Bunes, A., Kłopotowska, M., Różańska, M., & Winiarska, M. (2015) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2015.06.016 · Cited by 33
Czuczman, M. S., Goy, A. H., Lamonica, D. M., Graf, D. A., Munteanu, M. C., & van der Jagt, R. H. (2015) · Annals of Hematology · doi:10.1007/s00277-015-2478-9 · Cited by 31
Self-citationClinicopathologic features and management of blastoid variant of mantle cell lymphoma
Shrestha, R. K., Bhatt, V. R., Murthy, G. S. G., & Armitage, J. O. (2015) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2015.1026902 · Cited by 31
Ibrutinib in mantle cell lymphoma patients: glass half full? Evidence and opinion
Stephens, D. M., & Spurgeon, S. E. F. (2015) · Therapeutic Advances in Hematology · doi:10.1177/2040620715592569 · Cited by 32
Self-citationCombinatorial BTK and MALT1 inhibition augments killing of CD79 mutant diffuse large B cell lymphoma
Nagel, D., Bognar, M., Eitelhuber, A. C., Kutzner, K., Vincendeau, M., & Krappmann, D. (2015) · Oncotarget · doi:10.18632/oncotarget.6273 · Cited by 31
Targeting BTK through microRNA in chronic lymphocytic leukemia
Bottoni, A., Rizzotto, L., Lai, T.-H., Liu, C., Smith, L. L., Mantel, R., Reiff, S. D., El‐Gamal, D., Larkin, K. T. M., Johnson, A. J., et al. (2016) · Blood · doi:10.1182/blood-2016-07-727750 · Cited by 31
Kozaki, R., Vogler, M., Walter, H. S., Jayne, S., Dinsdale, D. D., Siebert, R., Dyer, M. J. S., & Yoshizawa, T. (2018) · Cancers · doi:10.3390/cancers10040127 · Cited by 31
Yi, S., Zou, D., Li, C., Zhong, S., Chen, W., Li, Z., Xiong, W., Liu, W., Liu, E., Cui, R., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5705 · Cited by 30
In Silico Identification of a Novel Hinge-Binding Scaffold for Kinase Inhibitor Discovery
Wang, Y., Sun, Y., Cao, R., Liu, D., Xie, Y., Li, L., Qi, X., & Huang, N. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01075 · Cited by 30
Self-citationAnticoagulation of Cardiovascular Conditions in the Cancer Patient: Review of Old and New Therapies
Rhea, I. B., Lyon, A. R., & Fradley, M. G. (2019) · Current Oncology Reports · doi:10.1007/s11912-019-0797-z · Cited by 30
Yao, X. Y., Sun, X., Jin, S., Yang, L. L., Xu, H., & Rao, Y. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00329 · Cited by 30
Jeon, Y., Yoon, S., Min, G. J., Park, S., Park, S., Yoon, J., Lee, S., Cho, B., Eom, K., Kim, Y., et al. (2019) · Cancer Medicine · doi:10.1002/cam4.2565 · Cited by 30
ADCs, BiTEs, CARs, and Small Molecules: A New Era of Targeted Therapy in Non-Hodgkin Lymphoma
Abramson, J. S., Ghosh, N., & Smith, S. M. (2020) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_279043 · Cited by 31
Minderman, M., Lantermans, H. C., Grüneberg, L. J., Cillessen, S. A. G. M., Bende, R. J., van Noesel, C. J. M., Kersten, M. J., Pals, S. T., & Spaargaren, M. (2023) · Blood Cancer Journal · doi:10.1038/s41408-023-00809-7 · Cited by 30
PRMT5 supports multiple oncogenic pathways in mantle cell lymphoma
Sloan, S. L., Brown-Burke, F., Long, M., Weigel, C., Koirala, S., Chung, J.-H., Pray, B. A., Villagomez, L., Hinterschied, C., Sircar, A., et al. (2023) · Blood · doi:10.1182/blood.2022019419 · Cited by 31
The Role of Adaptive Immunity in the Efficacy of Targeted Cancer Therapies
Xu, M. M., Pu, Y., Zhang, Y., & Fu, Y. (2016) · Trends in Immunology · doi:10.1016/j.it.2015.12.007 · Cited by 31
Li, J., Wang, X., Xie, Y., Ying, Z., Liu, W., Ping, L., Zhang, C., Pan, Z., Ding, N., Song, Y., et al. (2017) · International Journal of Cancer · doi:10.1002/ijc.31044 · Cited by 30
de la Bellacasa, R. P., Roué, G., Balsas, P., Pérez‐Galán, P., Teixidó, J., Colomer, D., & Borrell, J. I. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.09.018 · Cited by 29
Ibrutinib-induced pneumonitis in patients with chronic lymphocytic leukemia
Mato, A. R., Islam, P., Daniel, C., Strelec, L. E., Kaye, A. H., Brooks, S., Ganetsky, A., Nasta, S. D., Porter, D. L., Svoboda, J., et al. (2015) · Blood · doi:10.1182/blood-2015-12-686873 · Cited by 29
Inhibition of the Bruton Tyrosine Kinase Pathway in B-Cell Lymphoproliferative Disorders
Castillo, J. J., Treon, S. P., & Davids, M. S. (2016) · The Cancer Journal · doi:10.1097/ppo.0000000000000170 · Cited by 30
Treatment for patients with relapsed/refractory mantle cell lymphoma: European-based recommendations
Dreyling, M. H., Aurer, I., Cortelazzo, S., Hermine, O., Heß, G., Jerkeman, M., Gouill, S. L., Ribrag, V., Trněný, M., Visco, C., et al. (2017) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2017.1403602 · Cited by 29
Self-citationSterner, R. M., & Kenderian, S. S. (2019) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000559 · Cited by 29
Kaliamurthi, S., Selvaraj, G., Selvaraj, C., Singh, S. K., Wei, D., & Peslherbe, G. H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22137071 · Cited by 29
McCloud, R. L., Yuan, K., Mahoney, K. E., Bai, D. L., Shabanowitz, J., Ross, M. M., Hunt, D. F., & Hsu, K. (2021) · Analytical Chemistry · doi:10.1021/acs.analchem.1c01591 · Cited by 29
Stephens, D. M., Huang, Y., Ruppert, A. S., Walker, J. S., Canfield, D., Cempre, C. B., Fu, Q., Baker, S. D., Hu, B., Shah, H., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-3867 · Cited by 29
Sawalha, Y., Goyal, S., Switchenko, J. M., Romancik, J. T., Kamdar, M. K., Greenwell, I. B., Hess, B. T., Isaac, K. M., Portell, C. A., Garcia, A. M., et al. (2023) · Blood Advances · doi:10.1182/bloodadvances.2022008916 · Cited by 29
Self-citationTargeting Interleukin-2 Inducible T-Cell Kinase (ITK) in T-Cell Related Diseases
Zhong, Y., Johnson, A. J., Byrd, J. C., & Dubovsky, J. A. (2014) · Postdoc Journal · doi:10.14304/surya.jpr.v2n6.1 · Cited by 29
Use of Biologics in Sjögren's Syndrome
Nocturne, G., Cornec, D., Séror, R., & Mariette, X. (2016) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2016.03.001 · Cited by 29
The role of B cell antigen receptors in mantle cell lymphoma
Fichtner, M. W., Dreyling, M. H., Binder, M., & Trepel, M. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0533-9 · Cited by 29
Self-citationYu, J., Chen, Y., Chen, L., Zhang, L., Rassenti, L. Z., Widhopf, G. F., & Kipps, T. J. (2018) · Oncotarget · doi:10.18632/oncotarget.25340 · Cited by 29
Self-citationBruton's tyrosine kinase inhibitors in B‐cell non‐Hodgkin's lymphomas
Alinari, L., Quinion, C. D., & Blum, K. (2015) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.65 · Cited by 28
Self-citationInhibition of Lyn is a promising treatment for mantle cell lymphoma with bortezomib resistance
Kim, A., Seong, K. M., Kang, H. J., Park, S., & Lee, S. (2015) · Oncotarget · doi:10.18632/oncotarget.5425 · Cited by 28
Bruton tyrosine kinase inhibitor ONO/GS-4059: from bench to bedside
Wu, J., Zhang, M., & Liu, D. (2016) · Oncotarget · doi:10.18632/oncotarget.12786 · Cited by 28
Kienle, D., & Stilgenbauer, S. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1737010 · Cited by 28
Self-citationRelapsed/Refractory Mantle Cell Lymphoma: Beyond BTK Inhibitors
Burkart, M., & Karmali, R. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12030376 · Cited by 28
Treatment Landscape of Relapsed/Refractory Mantle Cell Lymphoma: An Updated Review
Al-Mansour, M. M. (2022) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2022.07.017 · Cited by 28
Divakar, S. K. A., Reddy, M. V. R., Cosenza, S. C., Baker, S. J., Perumal, D., Antonelli, A. C., Brody, J., Akula, B., Parekh, S. S., & Reddy, E. P. (2015) · Leukemia · doi:10.1038/leu.2015.185 · Cited by 28
In pursuit of a moving target: nanotherapeutics for the treatment of non-Hodgkin B-cell lymphoma
Knapp, C. M., & Whitehead, K. A. (2014) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2014.945419 · Cited by 28
Phosphodiesterase 4 inhibitors have wide-ranging activity in B-cell malignancies
Cooney, J. D., & Aguiar, R. C. T. (2016) · Blood · doi:10.1182/blood-2016-09-737676 · Cited by 29
Salcedo, L. M. J., Sandoval-Sus, J. D., Sokol, L., Chávez, J. C., & Dalia, S. M. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.02.027 · Cited by 30
Lombardo, K. A., Coffey, D. G., Morales, A. J., Carlson, C. S., Towlerton, A. M. H., Gerdts, S. E., Nkrumah, F., Neequaye, J. E., Biggar, R. J., Orem, J., et al. (2017) · Blood Advances · doi:10.1182/bloodadvances.2016000794 · Cited by 28
Crosstalk between ROR1 and BCR pathways defines novel treatment strategies in mantle cell lymphoma
Karvonen, H., Chiron, D., Niininen, W., Ek, S., Jerkeman, M., Moradi, E., Nykter, M., Heckman, C. A., Kallioniemi, O., Murumägi, A., et al. (2017) · Blood Advances · doi:10.1182/bloodadvances.2017010215 · Cited by 28
Gemenetzi, K., Agathangelidis, A., Zaragoza‐Infante, L., Sofou, E., Papaioannou, M., Chatzidimitriou, A., & Σταματόπουλος, Κ. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00067 · Cited by 28
Soumerai, J. D., Barrientos, J. C., Ahn, I. E., Coombs, C. C., Gladstone, D. E., Hoffmann, M. S., Kittai, A. S., Jacobs, R. W., Lipsky, A. H., Patel, K., et al. (2024) · Blood Advances · doi:10.1182/bloodadvances.2024014474 · Cited by 27
Self-citationMolecular Pathways: Targeting MALT1 Paracaspase Activity in Lymphoma
Fontán, L., & Melnick, A. M. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3869 · Cited by 29
Venetoclax Synergizes with Radiotherapy for Treatment of B-cell Lymphomas
O’Steen, S., Green, D. J., Gopal, A. K., Orozco, J. J., Kenoyer, A. L., Lin, Y., Wilbur, D. S., Hamlin, D. K., Fisher, D. R., Hylarides, M. D., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0082 · Cited by 27
Schäffer, M., Chaturvedi, S., Davis, C., Aquino, R., Stepanchick, E., Versele, M., Liu, Y., Yang, J., Lu, R., & Balasubramanian, S. (2017) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2017.1349899 · Cited by 28
Synergistic effect of ibrutinib and CD19 CAR‐T cells on Raji cells in vivo and in vitro
Liu, M., Wang, X., Li, Z., Zhang, R., Mu, J., Jiang, Y., Deng, Q., & Sun, L. (2020) · Cancer Science · doi:10.1111/cas.14638 · Cited by 27
Jain, N. K., Mamgain, M., Chowdhury, S. M., Jindal, U., Sharma, I., Sehgal, L., & Epperla, N. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01496-4 · Cited by 27
Ibrutinib-A double-edge sword in cancer and autoimmune disorders
Kokhaei, P., Jadidi‐Niaragh, F., Jahromi, A. S., Österborg, A., Mellstedt, H., & Hojjat‐Farsangi, M. (2015) · Journal of drug targeting · doi:10.3109/1061186x.2015.1086357 · Cited by 27
Type I Cytokines Synergize with Oncogene Inhibition to Induce Tumor Growth Arrest
Acquavella, N., Clever, D. C., Yu, Z., Parker, M. R., Palmer, D. C., Xi, L., Pflicke, H., Ji, Y., Gros, A., Hanada, K., et al. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0122 · Cited by 27
Ibrutinib-associated pityriasis rosea–like rash
Bitar, C., Sadeghian, A., Sullivan, L. L., & Murina, A. (2017) · JAAD Case Reports · doi:10.1016/j.jdcr.2017.06.035 · Cited by 27
Holte, H., Beiske, K., Boyle, M., Trøen, G., Blaker, Y. N., Myklebust, J. H., Kvaløy, S., Rosenwald, A., Lingjærde, O. C., Rimsza, L. M., et al. (2018) · British Journal of Haematology · doi:10.1111/bjh.15518 · Cited by 27
Treatment of mantle cell lymphoma in Asia: a consensus paper from the Asian Lymphoma Study Group
Yoon, D. H., Cao, J., Chen, T., Izutsu, K., Kim, S. J., Kwong, Y., Lin, T. Y., Thye, L. S., Xu, B., Yang, D., et al. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00855-9 · Cited by 27
Extrahepatic metabolism of ibrutinib
Rood, J. J. M., Jamalpoor, A., van Hoppe, S., van Haren, M. J., Wasmann, R. E., Janssen, M. J., Schinkel, A. H., Masereeuw, R., Beijnen, J. H., & Sparidans, R. W. (2020) · Investigational New Drugs · doi:10.1007/s10637-020-00970-x · Cited by 27
Current Approaches to Mantle Cell Lymphoma: Diagnosis, Prognosis, and Therapies
Cohen, J. B., Zain, J. M., & Kahl, B. S. (2017) · American Society of Clinical Oncology Educational Book · doi:10.14694/edbk_175448 · Cited by 26
Self-citationA FOXO1-dependent transcription network is a targetable vulnerability of mantle cell lymphomas
Jang, J.-Y., Hwang, I., Pan, H., Yao, J., Alinari, L., Imada, E. L., Zanettini, C., Kluk, M., Wang, Y., Lee, Y., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci160767 · Cited by 26
Effect of kinase inhibitors on the therapeutic properties of monoclonal antibodies
Duong, M. N., Matera, E., Mathé, D., Evesque, A., Valsesia‐Wittmann, S., Clemenceau, B., & Dumontet, C. (2014) · mAbs · doi:10.4161/19420862.2015.989020 · Cited by 27
Rushworth, S. A., Pillinger, G., Abdul-Aziz, A. M., Piddock, R. E., Shafat, M. S., Murray, M. Y., Zaitseva, L., Lawes, M. J., MacEwan, D. J., & Bowles, K. M. (2015) · The Lancet Haematology · doi:10.1016/s2352-3026(15)00046-0 · Cited by 26
Lenalidomide in relapsed or refractory mantle cell lymphoma: overview and perspective
Desai, M., Newberry, K. J., Ou, Z., Wang, M. L., & Zhang, L. (2014) · Therapeutic Advances in Hematology · doi:10.1177/2040620714532124 · Cited by 26
Self-citationEfficient bioreductive production of (S)-N-Boc-3-hydroxypiperidine using ketoreductase ChKRED03
Xu, G.-P., Wang, H.-B., & Wu, Z. (2016) · Process Biochemistry · doi:10.1016/j.procbio.2016.04.008 · Cited by 26
Rauert‐Wunderlich, H., Rudelius, M., Berberich, I., & Rosenwald, A. (2018) · Cell Death and Disease · doi:10.1038/s41419-017-0157-6 · Cited by 26
Simons, C., Malone, D. C., Wang, M. L., Maglinte, G. A., Inocencio, T. J., Wade, S. W., Bennison, C., & Shah, B. D. (2021) · Journal of Medical Economics · doi:10.1080/13696998.2021.1894158 · Cited by 26
Self-citationPandey, M. K., Gowda, K., Sung, S., Abraham, T., Budak-Alpdoǧan, T., Talamo, G., Dovat, S., & Amin, S. (2017) · Experimental Hematology · doi:10.1016/j.exphem.2017.06.003 · Cited by 26
Danilov, A. V., & Persky, D. O. (2020) · British Journal of Haematology · doi:10.1111/bjh.17184 · Cited by 25
Role of Specific B-Cell Receptor Antigens in Lymphomagenesis
Thurner, L., Hartmann, S., Neumann, F., Hoth, M., Stilgenbauer, S., Küppers, R., Preuss, K., & Bewarder, M. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.604685 · Cited by 26
Self-citationFollicular Lymphoma–associated BTK Mutations are Inactivating Resulting in Augmented AKT Activation
Hu, N., Wang, F., Sun, T., Xu, Z., Zhang, J., Bernard, D., Xu, S., Wang, S., Kaminski, M. S., Devata, S., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3741 · Cited by 26
Evolving frontline immunochemotherapy for mantle cell lymphoma and the impact on survival outcomes
Castellino, A., Wang, Y., Larson, M. C., Maurer, M. J., Link, B. K., Farooq, U., Feldman, A. L., Syrbu, S., Habermann, T. M., Paludo, J., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2021005715 · Cited by 25
Self-citationDiamond, A., Bensken, W. P., Vu, L., Dong, W., Koroukian, S. M., & Caimi, P. F. (2023) · JACC CardioOncology · doi:10.1016/j.jaccao.2023.02.001 · Cited by 26
Troussard, X., Maître, E., & Paillassa, J. (2024) · American Journal of Hematology · doi:10.1002/ajh.27240 · Cited by 25
Advances in the diagnosis and treatment of childhood and adolescent B-cell non-Hodgkin lymphoma.
El‐Mallawany, N. K., & Cairo, M. S. (2015) · PubMed · Cited by 25
Inwards, D. J., Fishkin, P. A. S., LaPlant, B. R., Drake, M. T., Kurtin, P. J., Nikcevich, D. A., Wender, D. B., Lair, B. S., & Witzig, T. E. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu273 · Cited by 25
Thurner, L., Hartmann, S., Fadle, N., Kemele, M., Bock, T., Bewarder, M., Regitz, E., Neumann, F., Nimmesgern, A., von Müller, L., et al. (2018) · Leukemia · doi:10.1038/s41375-018-0182-1 · Cited by 25
Discovery of potent, highly selective covalent irreversible BTK inhibitors from a fragment hit
Qiu, H., Liu‐Bujalski, L., Caldwell, R. D., Follis, A. V., Gardberg, A. S., Goutopoulos, A., Grenningloh, R., Head, J. C., Johnson, T. L., Jones, R. C., et al. (2018) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2018.07.008 · Cited by 25
Metabolic Detection of Bruton's Tyrosine Kinase Inhibition in Mantle Cell Lymphoma Cells
Lee, S., Shestov, A. A., Guo, L., Zhang, Q., Roman, J. C., Liu, X., Wang, H. Y., Pickup, S., Nath, K., Lu, P., et al. (2019) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-18-0256 · Cited by 26
Ran, F., Liu, Y., Liu, M., Zhang, D., Wang, P., Dong, J., Tang, W., & Zhao, G. (2019) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2019.102943 · Cited by 25
Davis, J. E., Handunnetti, S. M., Ludford‐Menting, M., Sharpe, C., Blombery, P. A., Anderson, M. A., Roberts, A. W., Seymour, J. F., Tam, C. S. L., Ritchie, D. S., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020002810 · Cited by 25
Dose Finding Study of Ibrutinib and Venetoclax in Relapsed or Refractory Mantle Cell Lymphoma
Portell, C. A., Wages, N. A., Kahl, B. S., Budde, L. E., Chen, R. W., Cohen, J. B., Varhegyi, N., Petroni, G. R., & Williams, M. E. (2021) · Blood Advances · doi:10.1182/bloodadvances.2021005357 · Cited by 25
Self-citationTreatment of relapsed/refractory MCL
Silkenstedt, E., & Dreyling, M. H. (2024) · Blood · doi:10.1182/blood.2023022353 · Cited by 24
Self-citationFrom development to clinical success: the journey of established and next-generation BTK inhibitors
Gupta, S., Sharma, A., Shukla, A. K., Mishra, A., & Singh, A. K. (2025) · Investigational New Drugs · doi:10.1007/s10637-025-01513-y · Cited by 25
EHA–EU MCL network guidelines for diagnosis and treatment of mantle cell lymphoma
Jerkeman, M., Aurer, I., Campo, E., Cheah, C. Y., Clark, J., Doorduijn, J. K., Eyre, T. A., Fehr, M., Giné, E., da Silva, M. G., et al. (2025) · HemaSphere · doi:10.1002/hem3.70233 · Cited by 24
Self-citationJordan, S. C., Choi, J., & Vo, A. A. (2015) · Immunotherapy · doi:10.2217/imt.15.10 · Cited by 24
Ghasoub, R. S., Albattah, A., Elazzazy, S., Al‐Okka, R., Nemir, A., Hijji, I. A., & Taha, R. Y. (2019) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155219856422 · Cited by 24
Management of Drug Resistance in Mantle Cell Lymphoma
Roué, G., & Sola, B. (2020) · Cancers · doi:10.3390/cancers12061565 · Cited by 27
Wang, J., Zhao, A., Zhou, H. F., Zhu, J., & Niu, T. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.580622 · Cited by 25
Zhu, C., Luo, X., Tian, T., Rao, Z., Wang, H., Zhou, Z., Gao, Z., Mi, T., Chen, D., Wu, Y., et al. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114459 · Cited by 24
Witzig, T. E., Zinzani, P. L., Habermann, T. M., Tuscano, J. M., Drach, J. W., Ramchandren, R., Beşışık, S. K., Takeshita, K., Bravo, M. C., Zhang, L., et al. (2017) · American Journal of Hematology · doi:10.1002/ajh.24854 · Cited by 24
Self-citationp110α Inhibition Overcomes Stromal Cell–Mediated Ibrutinib Resistance in Mantle Cell Lymphoma
Guan, J., Huang, D., Yakimchuk, K., & Okret, S. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0784 · Cited by 25
Nguyen, T., Parker, R. E., Zhang, Y., Hawkins, E., Kmieciak, M., Craun, W., & Grant, S. (2018) · BMC Cancer · doi:10.1186/s12885-018-5018-x · Cited by 24
Lee, D. H., Kim, G. W., & Kwon, S. H. (2019) · Molecular Carcinogenesis · doi:10.1002/mc.22983 · Cited by 24
Mantle cell lymphoma: therapeutic options in transplant-ineligible patients
Robak, T., Smolewski, P., Robak, P. J., & Dreyling, M. H. (2019) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2019.1605511 · Cited by 24
Self-citationEfficacy of the novel CDK7 inhibitor QS1189 in mantle cell lymphoma
Choi, Y. J., Kim, D. H., Yoon, D. H., Suh, C., Choi, C., Lee, J. C., Hong, J. Y., & Rho, J. K. (2019) · Scientific Reports · doi:10.1038/s41598-019-43760-z · Cited by 24
Recent Advances in CAR-T Cell Therapy for Non-Hodgkin Lymphoma
Kallam, A., & Vose, J. M. (2019) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2019.09.598 · Cited by 26
Rule, S. A., Cartron, G., Fegan, C., Morschhauser, F., Han, L., Mitra, S. S., Salles, G. A., & Dyer, M. J. S. (2019) · Leukemia · doi:10.1038/s41375-019-0658-7 · Cited by 24
Self-citationLukas, M., Velten, B., Sellner, L., Tomska, K., Hüellein, J., Walther, T., Wagner, L., Muley, C., Wu, B., Oleś, M., et al. (2020) · Leukemia · doi:10.1038/s41375-020-0846-5 · Cited by 25
Sharman, J. P., Kabadi, S., Clark, J., & Andorsky, D. J. (2020) · British Journal of Haematology · doi:10.1111/bjh.16922 · Cited by 24
Metadata
- Authors
- Wang, M. L., Rule, S., Martin, P., Goy, A., Auer, R., Kahl, B. S., Jurczak, W., Advani, R. H., Romaguera, J. E., Williams, M. E., Barrientos, J. C., Chmielowska, E., Radford, J., Stilgenbauer, S., Dreyling, M., Jedrzejczak, W. W., Johnson, P., Spurgeon, S. E., Li, L., Zhang, L., Newberry, K., Ou, Z., Cheng, N., Fang, B., McGreivy, J., Clow, F., Buggy, J. J., Chang, B. Y., Beaupre, D. M., Kunkel, L. A., & Blum, K. A.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- Derriford Hospital (GB)
- Weill Cornell Medicine (US)
- Hackensack University Medical Center (US)
- University of Wisconsin–Madison (US)
- Jagiellonian University (PL)
- Stanford Medicine (US)
- University of Virginia (US)
- Northwell Health (US)
- Centrum Onkologii (PL)
- University of Manchester (GB)
- University Hospital Ulm (DE)
- LMU Klinikum (DE)
- Cancer Research UK (GB)
- Oregon Health & Science University (US)
- Pharmacyclics (United States) (US)
- The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (US)
- ORCID
- Wang, Michael L.
- Rule, Simon
- Martin, Peter
- Goy, Andre
- Auer, Rebecca
- Kahl, Brad S.
- Jurczak, Wojciech
- Advani, Ranjana H.
- Romaguera, Jorge E.
- Williams, Michael E.
- Barrientos, Jacqueline C.
- Radford, John
- Stilgenbauer, Stephan
- Dreyling, Martin
- Johnson, Peter
- Spurgeon, Stephen E.
- Li, Lei
- Zhang, Liang
- Newberry, Kate
- Fang, Bingliang
- Chang, Betty Y.
- Blum, Kristie A.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2013-08-08
- Volume
- 369
- Issue
- 6
- Pages
- 507-516
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC4513941
- OpenAlex
- W2154066874
- Cited by
- 1,685
- References
- 39
- Citations by year
- 2026: 59 · 2025: 67 · 2024: 91 · 2023: 115 · 2022: 142 · 2021: 127 · 2020: 138 · 2019: 127 · 2018: 141 · 2017: 161 · 2016: 133 · 2015: 189 · 2014: 147 · 2013: 42
- FWCI
- 127.66
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Research Explorer (The University of Manchester) (submittedVersion)
- Homo Politicus (Academy of Humanities and Economics in Lodz) (submittedVersion, cc-by-nc-nd)
- Jagiellonian University Repository (Jagiellonian University) (submittedVersion, cc-by-nc-nd)
- Funders
- American Society of Hematology
- Amgen
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Gilead Sciences
- Celgene
- Massachusetts Medical Society
- Les Laboratories Pierre Fabre
- Genentech
- Pharmacyclics
- National Cancer Institute (P30CA014520)
- Janssen Biotech
- Topics
- Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Health Sciences › Medicine › Clinical Neurology › CNS Lymphoma Diagnosis and Treatment
- Keywords
- ibrutinib, BTK inhibitors, mantle cell lymphoma, relapsed/refractory lymphoma, bortezomib, B cell receptor signaling, oral BTK inhibitor, overall response rate, progression-free survival, overall survival, adverse events, neutropenia
- MeSH terms
- Agammaglobulinaemia Tyrosine Kinase, Adenine, Administration, Oral, Adult, Aged, Aged, 80 and over, Female, Humans, Male, Middle Aged, Piperidines, Protein-Tyrosine Kinases, Pyrazoles, Pyrimidines, Recurrence, Survival Analysis, Lymphocyte Count, Drug Resistance, Neoplasm, Lymphoma, Mantle-Cell, Protein Kinase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
